

# Brent L Wood

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1155829/publications.pdf>

Version: 2024-02-01

198  
papers

15,529  
citations

44444

50  
h-index

21239

119  
g-index

200  
all docs

200  
docs citations

200  
times ranked

17863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
2	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	13.7	1,430
3	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra116.	5.8	832
4	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	0.6	796
5	Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies. <i>Cancer Prevention Research</i> , 2012, 5, 492-497.	0.7	784
6	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	9.4	693
7	Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2017, 3, e170580.	3.4	388
8	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	9.4	384
9	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	13.9	352
10	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016, 34, 329-336.	0.8	347
11	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013, 122, 1813-1821.	0.6	325
12	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	0.6	305
13	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	0.8	301
14	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	0.6	287
15	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	9.4	264
16	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	0.6	236
17	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 56-67.	1.2	234
18	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	5.8	218

#	ARTICLE	IF	CITATIONS
19	Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019, 134, 1585-1597.	0.6	209
20	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	1.7	206
21	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	7.7	201
22	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	0.8	185
23	A phase I/II trial of iodine-131-antitumor necrosis factor-Î² (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	0.6	173
24	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	0.6	170
25	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	0.8	164
26	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018, 131, 1350-1359.	0.6	158
27	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 315-323.	0.7	153
28	Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i> . <i>Clinical Cancer Research</i> , 2014, 20, 4540-4548.	3.2	138
29	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	0.8	136
30	Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. <i>Blood Reviews</i> , 2017, 31, 63-75.	2.8	128
31	9-Color and 10-Color Flow Cytometry in the Clinical Laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 680-690.	1.2	124
32	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	0.8	121
33	Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 47-53.	0.7	118
34	Four-Color Flow Cytometry Shows Strong Concordance With Bone Marrow Morphology and Cytogenetics in the Evaluation for Myelodysplasia. <i>American Journal of Clinical Pathology</i> , 2005, 124, 170-181.	0.4	116
35	Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. <i>Blood</i> , 2017, 130, 811-811.	0.6	109
36	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	0.8	107

#	ARTICLE	IF	CITATIONS
37	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	0.6	97
38	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95
39	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	0.8	93
40	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol (<i>Escherichia coli</i>) L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	0.8	91
41	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	0.6	91
42	A novel flow cytometric assay for detection of residual disease in patients with B-cell lymphoblastic leukemia/lymphoma post anti-CD19 therapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 112-120.	0.7	84
43	Multicolor Immunophenotyping: Human Immune System Hematopoiesis. <i>Methods in Cell Biology</i> , 2004, 75, 559-576.	0.5	76
44	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	0.8	76
45	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	0.8	64
46	Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Leukemia Research and Treatment</i> , 2014, 2014, 1-9.	2.0	63
47	Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 256-265.	0.7	59
48	Flow Cytometric Monitoring of Residual Disease in Acute Leukemia. <i>Methods in Molecular Biology</i> , 2013, 999, 123-136.	0.4	57
49	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	0.8	56
50	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	0.8	54
51	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 575-585.	2.5	52
52	T-Cell Clonality Determination Using Polymerase Chain Reaction (PCR) Amplification of the T-Cell Receptor gamma-Chain Gene and Capillary Electrophoresis of Fluorescently Labeled PCR Products. <i>American Journal of Clinical Pathology</i> , 2000, 113, 838-850.	0.4	51
53	Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 204-204.	0.6	50
54	Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. <i>Modern Pathology</i> , 2014, 27, 1438-1446.	2.9	49

#	ARTICLE	IF	CITATIONS
55	Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. <i>Current Protocols in Cytometry</i> , 2020, 93, e73.	3.7	49
56	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , 2015, 126, 184-184.	0.6	49
57	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part I - rationale and aims. , 2013, 84, 282-285.		48
58	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	3.3	48
59	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
60	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 691-696.	2.0	46
61	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	2.0	46
62	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	0.8	45
63	Four-Color Flow Cytometry Identifies Virtually All Cytogenetically Abnormal Bone Marrow Samples in the Workup of Non-CML Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2003, 120, 854-865.	0.4	44
64	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	0.6	44
65	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	0.8	44
66	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	0.8	42
67	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	0.8	41
68	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	3.3	40
69	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3773-3773.	0.6	39
70	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
71	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1227-1233.	2.0	36
72	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	3.9	36

#	ARTICLE	IF	CITATIONS
73	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	0.8	36
74	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	1.2	35
75	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.2	32
76	Mixed phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	2.0	32
77	Methods of Detection of Measurable Residual Disease in AML. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 557-567.	1.2	31
78	CD44 promotes chemoresistance in T-ALL by increased drug efflux. <i>Experimental Hematology</i> , 2016, 44, 166-171.e17.	0.2	29
79	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1615-1620.	2.0	29
80	Evaluation of allogeneic transplantation in first or later minimal residual disease negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	0.6	28
81	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. <i>Haematologica</i> , 2017, 102, 1549-1557.	1.7	28
82	How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 237-248.	0.7	28
83	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020, 12, 2339.	1.7	28
84	Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated <i>NPM1</i> . <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 67-72.	0.7	26
85	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	1.7	25
86	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	0.6	24
87	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction. A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009, 114, 9-9.	0.6	24
88	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 211-211.	0.6	24
89	Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. <i>American Journal of Pathology</i> , 2017, 187, 304-317.	1.9	22
90	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. <i>Biomarker Research</i> , 2020, 8, 29.	2.8	22

#	ARTICLE	IF	CITATIONS
91	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	3.3	22
92	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. <i>Blood</i> , 2021, 137, 569-572.	0.6	21
93	Human <sc>B</sc>-cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 214-226.	0.7	20
94	Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.. <i>Journal of Clinical Oncology</i> , 2016, 34, 102-102.	0.8	20
95	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	0.8	19
96	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. <i>Blood</i> , 2013, 122, 1341-1341.	0.6	19
97	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
98	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	2.8	17
99	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e97-e98.	1.7	16
100	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
101	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020, 34, 1701-1705.	3.3	15
102	Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3006-3006.	0.8	15
103	Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase. <i>Blood</i> , 2019, 134, 1856-1856.	0.6	14
104	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	0.6	14
105	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	3.3	14
106	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018, 93, 546-552.	2.0	13
107	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 669-672.	1.3	13
108	Computer-Aided Detection of Rare Tumor Populations in Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2015, 144, 517-524.	0.4	12

#	ARTICLE	IF	CITATIONS
109	Flow cytometric features of incidental indolent T lymphoblastic proliferations. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 282-287.	0.7	12
110	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013, 122, 2550-2550.	0.6	12
111	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	2.0	12
112	Clinical Experience With Modified, Single-Tube T-Cell Receptor V $\beta$ 2 Flow Cytometry Analysis for T-Cell Clonality. <i>American Journal of Clinical Pathology</i> , 2016, 145, 467-485.	0.4	11
113	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	1.7	11
114	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 300-309.	0.7	11
115	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2479-2483.	3.3	11
116	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky069.	1.4	10
117	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29256.	0.8	10
118	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020, 136, 11-12.	0.6	10
119	Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33. <i>Blood</i> , 2007, 110, 159-159.	0.6	10
120	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 256-256.	0.6	10
121	Measurable Residual Disease Detection in Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method. <i>Current Protocols</i> , 2022, 2, e383.	1.3	10
122	Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 387-392.	0.7	9
123	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2016, 172, 134-136.	1.2	9
124	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. <i>Methods in Molecular Biology</i> , 2019, 1956, 35-60.	0.4	9
125	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	0.8	9
126	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622. <i>Journal of Clinical Oncology</i> , 2015, 33, 10006-10006.	0.8	9



#	ARTICLE	IF	CITATIONS
127	Flow cytometry in the diagnosis and monitoring of acute leukemia in children. <i>Journal of Hematopathology</i> , 2015, 8, 191-199.	0.2	8
128	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	0.8	8
129	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019, 33, 554-558.	3.3	8
130	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after "Day 14"™ without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2717-2719.	0.6	7
131	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	0.6	7
132	Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. <i>Blood</i> , 2020, 136, 11-12.	0.6	7
133	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009, 114, 1580-1580.	0.6	7
134	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	0.8	7
135	Plasma polychlorinated biphenyl concentrations and immune function in postmenopausal women. <i>Environmental Research</i> , 2014, 131, 174-180.	3.7	6
136	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018, 16, 42-52.	0.5	6
137	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. <i>Blood</i> , 2019, 134, 824-824.	0.6	6
138	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. <i>Blood</i> , 2020, 136, 45-46.	0.6	6
139	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	3.3	6
140	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	6
141	Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an <i>NRAS</i> Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1667-1670.	0.8	5
142	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	0.6	5
143	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 649-649.	0.6	5
144	CD44H and CD44V6 Expression in Different Subtypes of Hodgkin Lymphoma. <i>Modern Pathology</i> , 2000, 13, 1121-1127.	2.9	4

#	ARTICLE	IF	CITATIONS
145	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 340-340.	0.6	4
146	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 251-255.	2.5	4
147	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10004-10004.	0.8	3
148	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1418-1418.	0.6	3
149	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10509-10509.	0.8	3
150	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2021, 13, 5607.	1.7	3
151	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021, 138, 3398-3398.	0.6	3
152	Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 15-15.	0.6	3
153	No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. <i>Experimental Hematology</i> , 2014, 42, 497-504.	0.2	2
154	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28574.	0.8	2
155	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	0.6	2
156	Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. <i>Blood</i> , 2013, 122, 882-882.	0.6	2
157	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	0.6	2
158	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. <i>Advances in Molecular Pathology</i> , 2021, 4, 49-63.	0.2	2
159	Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2019, 134, 1475-1475.	0.6	2
160	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
161	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 1511-1514.	1.3	1
162	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. <i>Blood</i> , 2019, 134, 2729-2729.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2569-2569.	0.6	1
164	The value of secondary pathology review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7-7.	0.8	1
165	VpreB Surrogate Light Chain Expression in B-Lineage ALL: A Report from the Children's Oncology Group. <i>Blood Advances</i> , 2021, , .	2.5	1
166	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009, 114, 2658-2658.	0.6	1
167	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , 2015, 126, 2571-2571.	0.6	1
168	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	0.6	1
169	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 614-614.	0.6	1
170	Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO. <i>Blood</i> , 2021, 138, 4475-4475.	0.6	1
171	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	0.6	1
172	Pre-B cell receptor expression in B-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19006-e19006.	0.8	0
173	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	0.8	0
174	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10003-10003.	0.8	0
175	In Vivo Expansion of Transduced Human Erythroid Cells Using an Mpl-Based Cell Growth Switch.. <i>Blood</i> , 2004, 104, 2100-2100.	0.6	0
176	Expansion of Genetically Modified Primary Human Hematopoietic Cells Using a Cell Growth Switch.. <i>Blood</i> , 2005, 106, 3044-3044.	0.6	0
177	Identification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical Hodgkin Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.. <i>Blood</i> , 2006, 108, 2262-2262.	0.6	0
178	A Characterization of Microparticles in Stored Packed Red Blood Cell Units.. <i>Blood</i> , 2006, 108, 4147-4147.	0.6	0
179	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012, 120, 655-655.	0.6	0
180	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. <i>Blood</i> , 2012, 120, 1440-1440.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3551-3551.	0.6	0
182	Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm. <i>Blood</i> , 2013, 122, 2614-2614.	0.6	0
183	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 1317-1317.	0.6	0
184	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18031-e18031.	0.8	0
185	Pathophysiology of Macrocytic Anemia in Diamond Blackfan Anemia and Del(5q) Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 670-670.	0.6	0
186	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016, 128, 2890-2890.	0.6	0
187	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018, 132, 5255-5255.	0.6	0
188	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018, 132, 3978-3978.	0.6	0
189	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018, 132, 889-889.	0.6	0
190	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018, 132, 659-659.	0.6	0
191	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10033-10033.	0.8	0
192	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019, 134, 2691-2691.	0.6	0
193	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019, 134, 321-321.	0.6	0
194	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. <i>Blood</i> , 2019, 134, 286-286.	0.6	0
195	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019, 134, 2692-2692.	0.6	0
196	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	0.6	0
197	Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States. <i>Blood</i> , 2021, 138, 4478-4478.	0.6	0
198	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 38-39.	0.6	0